RT Journal Article
SR Electronic
T1 Combined Metabolic Activators Improve Cognitive Functions without Altering Motor Scores in Parkinson’s Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.28.21261293
DO 10.1101/2021.07.28.21261293
A1 Yulug, Burak
A1 Altay, Ozlem
A1 Li, Xiangyu
A1 Hanoglu, Lutfu
A1 Cankaya, Seyda
A1 Lam, Simon
A1 Yang, Hong
A1 Coskun, Ebru
A1 İdil, Ezgi
A1 Nogaylar, Rahim
A1 Hacımuftuoglu, Ahmet
A1 Arif, Muhammad
A1 Shoaie, Saeed
A1 Zhang, Cheng
A1 Nielsen, Jens
A1 Turkez, Hasan
A1 Borén, Jan
A1 Uhlén, Mathias
A1 Mardinoglu, Adil
YR 2021
UL http://medrxiv.org/content/early/2021/08/04/2021.07.28.21261293.abstract
AB The neuropathologic hallmarks of Parkinson’s disease (PD) are associated with mitochondrial dysfunction and metabolic abnormalities. We have reported that the Combined Metabolic Activators (CMA), consisting of L-serine, nicotinamide riboside, N-acetyl-L-cysteine, and L-carnitine tartrate can be used in treating metabolic abnormalities. These metabolic activators are the precursors of nicotinamide adenine dinucleotide (NAD+) and glutathione (GSH) and used in activation of mitochondrial and global metabolism. We have performed a placebo-controlled, phase-2 study in Alzheimer’s disease (AD) patients and reported that the cognitive functions in AD patients is significantly improved 29% in the CMA group whereas it is improved only 14% in the placebo group after 84 days of CMA administration. Here, we designed a randomized, double-blinded, placebo-controlled, phase-2 study in PD patients with CMA administration. We found that the cognitive functions in PD patients is significantly improved 21% in the CMA group, whereas it is improved only 11% in the placebo group after 84 days of CMA administration. We also found that the administration of CMA did not affect motor functions in PD patients. We performed a comprehensive multi-omics analysis of plasma proteins and metabolites, and revealed the molecular mechanism associated with the treatment of the patients. In conclusion, our results show that treating PD patients with CMAs leads to enhanced cognitive function, as recently reported in AD patients.Competing Interest StatementAM, JB and MU are the founder and shareholders of ScandiBio Therapeutics. The other authors declare no competing interests.Clinical TrialNCT04044131Funding StatementThis work was financially supported by ScandiBio Therapeutics and Knut and Alice Wallenberg Foundation. The authors would like to thank Metabolon Inc. (Durham, USA) for generating metabolomics data and ChromaDex Inc. (Irvine, CA, USA) for providing NR. AM and HY acknowledge support from the PoLiMeR Innovative Training Network (Marie Sklodowska-Curie Grant Agreement No. 812616), which received funding from the European Union's Horizon 2020 research and innovation programme.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of Istanbul Medipol University, Istanbul, TurkeyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll available data included in the supplementary datasets